Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.